Company Information

Location

Cambridge, MA

CEO

Samantha Truex

Website

quenchbio.com

Led by a team of drug developers and scientists with deep experience in inflammation and small molecule drug discovery, Quench Bio’s lead therapeutic approach centers on inhibiting the protein Gasdermin D, which has been recently discovered as a key target at the core of multiple inflammatory cell death pathways, including pyroptosis and NETosis. When pyroptosis or NETosis pathways are activated, gasdermin is processed and forms lytic pores on the cell membrane, allowing release of inflammatory cytokines, alarmins, DNA and NETs. Pyroptosis and NETosis are associated with numerous inflammatory diseases, including rheumatoid arthritis, lupus, multiple sclerosis and nonalcoholic steatohepatitis (NASH), among others.

Arix and Atlas Venture co-founded and seeded the company in 2018 along with co-founders Mark Tebbe, Ph.D., Chief Technology Officer, and Mike Nolan, Ph.D., Head of Biology, together with Arturo Zychlinsky and Herbert Waldmann, both Directors at The Max Planck Institute who collaborated with the Lead Discovery Center on inhibitors of NETosis and gasdermin. The company has since built a highly experienced leadership team, led by Chief Executive Officer Samantha Truex the former CBO of Padlock Therapeutics, which was acquired by Bristol Myers Squibb in 2016.